Prognostic value of combined p53 and survivin in pt1g3 urothelial carcinoma of the bladder

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 232-237

  Gonzalez, Samia ^a,b   Aubert, Sébastien ^a   Kerdraon, Olivier ^a   Haddad, Olivier ^a   Fantoni, Jean Christophe ^a   Biserte, Jacques ^a   Leroy, Xavier ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Centre de Biologie Pathologie   (France)

Author keywords

Bladder cancer; Micrometric measurement; p53; pT1a pT1b substaging; pT1G3; Superficial urothelial tumor; Survivin

Indexed keywords

PROTEIN P53; SURVIVIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; RARRES3 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER MORTALITY; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOSCOPIC SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SUBMUCOSA; TUMOR GROWTH; TUMOR RECURRENCE; UROGENITAL TRACT TUMOR; BLADDER TUMOR; DISEASE COURSE; EVALUATION; METABOLISM; PATHOLOGY;

DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, RETINOIC ACID; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 40449115151     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/2TY6GTV1GQ6B5ARM     Document Type: Article

References (39)

1. Sauter G, Albagha F, Amin M, et al. Tumours of the urinary system. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:89-123.
2. Irani J, Bernardini S, Bonnal JL, et al. Urothelial tumors. Prog Urol. 2004;14:957, 959-996.
3. Gattegno B, Chopin D. Natural history of superficial bladder tumors. Prog Urol. 2001;11:963-990.
4. Malavaud B. T1G3 bladder tumors: the case for radical cystectomy. Eur Urol. 2004;45:406-410.
5. Billerey C, Sibony M, Gattegno B, et al. Pathologic anatomy of superficial tumors of the bladder. Prog Urol. 2001;11:805-863.
6. Cheng L, Weaver AL, Neumann RM, et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer. 1999;86:1035-1043.
7. Ku JH, Kwak C, Lee HS, et al. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol. 2004;171:631-635.
8. Pizem J, Cor A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology. 2004;45:180-186.
9. Hölmang S, Hedelin H, Anderstrom C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997;157:800-804.
10. Greene FL, Page DL, Fleming ID, et al; for the American Joint Committee on Cancer, eds. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
11. Joudi FN, Smith BJ, O'Donnell MA, et al. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology. 2003;62:1083-1088.
12. Smits G, Schaafsma E, Kiemeney L, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 1998;52:1009-1014.
13. Weaver MG, Abdul-Karim FW. The prevalence and character of the muscularis mucosae of the human urinary bladder. Histopathology. 1990;17:563-566.
14. Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder: importance for staging and treatment. Am J Surg Pathol. 1987;11:668-673.
15. Cheng L, Neumann RM, Weaver AL, et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol. 1999;17:3182-3187.
16. van der Aa MN, van Leenders GJ, Steyerberg EW, et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol. 2005;36:981-986.
17. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-547.
18. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 2005;114:509-512.
19. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer [letter]. N Engl J Med. 1999;341:452-453.
20. Lehner R, Lucia MS, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol. 2002;10:134-138.
21. Nakanishi K, Tominaga S, Hiroi S, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2002;441:559-563.
22. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;10:1259-1264.
23. Hitchings AW, Kumar M, Jordan S, et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer. 2004;2:552-557.
24. Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829-834.
25. Shariat S F, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;2:481-487.
26. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;15:1007-1013.
27. Lacombe L, Dalbagni G, Zhang Z F, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol. 1996;14:2646-2652.
28. Dalbagni G, Parekh DJ, Ben-Porat L, et al. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007;99:281-285.
29. Gardiner RA, Walsh MD, Allen V, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol. 1994;73:526-532.
30. Esuvaranathan K, Chiong E, Thamboo T P, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer. 2007;15:1097-1105.
31. Malats N, Bustos A, Nascimento CM, et al. p53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678-686.
32. Hernandez S, Lopez-Knowles E, Lloreta J, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res. 2005;11:5444-5450.
33. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8:128-136.
34. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
35. Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886-892.
36. Tsuji N, Furuse K, Asanuma K, et al. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer. Breast Cancer Res Treat. 2004;87:23-31.
37. Nakano J, Huang CL, Liu D, et al. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol. 2005;27:1215-1221.
38. Kannangai R, Wang J, Liu QZ, et al. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer. 2005;35:53-60.
39. Sah NK, Khan Z, Khan GJ, et al. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244:164-171.